GOSS

Gossamer Bio Inc

Add to Watchlist

Advanced Chart

1.840

+0.06(3.371%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.920

Open

1.790

VWAP

1.83

Vol

2.09M

Mkt Cap

418.24M

Low

1.720

Amount

3.83M

EV/EBITDA(TTM)

Total Shares

226.22M

358.07M

EV/OCF(TTM)

39.30

P/S(TTM)

Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

5.24M

-44.76%

4.71M

-95.09%

Estimates Revision

The market is revising Upward the revenue expectations for Gossamer Bio, Inc. (GOSS) for FY2025, with the revenue forecasts being adjusted by 28.55% over the past three months. During the same period, the stock price has changed by 109.95%.

Revenue Estimates for FY2025

Revise Upward

+28.55%

In Past 3 Month

Stock Price

Go Up

+109.95%

In Past 3 Month

6 Analyst Rating

375.54% Upside

Wall Street analysts forecast GOSS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GOSS is 8.75 USD with a low forecast of 4.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

1 Hold

0 Sell

Strong Buy

375.54% Upside

Current: 1.840

Low

4.00

Averages

8.75

High

15.00

375.54% Upside

Current: 1.840

Low

4.00

Averages

8.75

High

15.00

Scotiabank

Outperform

initiated

$11

2025-07-14

Reason

Scotiabank

Price Target

$11

2025-07-14

initiated

Outperform

Reason

Scotiabank initiated coverage of Gossamer Bio with an Outperform rating and $11 price target. The firm likes the company's approach in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Gossamer's lead asset seralutinib could see significant uptake given its novel mechanism of action as an inhaled tyrosine kinase inhibitor, the analyst tells investors in a research note. Scotiabank thinks the therapy to be an adjunct to standard of care.

Goldman Sachs

Paul Choi

Strong Buy

Maintains

$8 → $7

2025-04-17

Reason

Goldman Sachs

Paul Choi

Price Target

$8 → $7

2025-04-17

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$10

2025-03-18

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$10

2025-03-18

Reiterates

Strong Buy

Reason

Wedbush

Laura Chico

Buy

Reiterates

2025-03-14

Reason

Wedbush

Laura Chico

Price Target

2025-03-14

Reiterates

Buy

Reason

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$10

2025-01-30

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$10

2025-01-30

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$10

2024-11-11

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$10

2024-11-11

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Gossamer Bio Inc (GOSS.O) is -2.65, compared to its 5-year average forward P/E of -2.49. For a more detailed relative valuation and DCF analysis to assess Gossamer Bio Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.49

Current PE

-2.65

Overvalued PE

-1.22

Undervalued PE

-3.76

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.90

Current EV/EBITDA

-3.19

Overvalued EV/EBITDA

-0.55

Undervalued EV/EBITDA

-3.25

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

22.15

Current PS

18.22

Overvalued PS

106.51

Undervalued PS

-62.20